The story has been updated to include comments from NeoGenomics' conference call on Wednesday.

NEW YORK (GenomeWeb) – NeoGenomics on Wednesday said that its fourth quarter revenues more than doubled year over year as clinical genetic test volumes also shot up, driven by the inclusion of Clarient's results.

NeoGenomics acquired Clarient from GE Healthcare Life Sciences at the end of 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.